Autonomic Nervous System - Week 10 Flashcards

(51 cards)

1
Q

Define adrenergic receptor antagonists.

A

Drugs that inhibit the interaction of NE, EPI, and other sympathomimetics with α- and β- adrenergic receptors are termed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Antagonism of ___________ __________ receptors is of little clinical relevance in veterinary medicine

A

peripheral dopaminergic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Prazosin, terazosin, doxazosin

  1. State which type of antagonist these drugs are.
A
  1. a1&raquo_space;» a2
  2. alpha-antagonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Phenoxybenzamine

  1. State which type of antagonist these drugs are.
A
  1. a1>a2
  2. alpha-antagonists
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Phenotolamine

  1. State which type of antagonist these drugs are.
A
  1. a1=a2
  2. alpha-antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Atipamezole, Yohimbine, Tolazoline

  1. State which type of antagonist these drugs are.
A
  1. a2»a1
  2. alpha-antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Carvedilol

  1. State which type of antagonist these drugs are.
A
  1. B1 = B2 >/= to a1 > a2
  2. mixed alpha and beta antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Propranolol, Timolol

  1. State which type of antagonist these drugs are.
A
  1. B1 = B2
  2. beta antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. Explain the receptor selectivity for alpha 1, alpha 2, beta 1, beta 2 receptors for the following antagonist(s):

Metoprolol, Atenolol, Esmolol, Betaxolol

  1. State which type of antagonist these drugs are.
A
  1. B1&raquo_space;> B2
  2. beta antagonist
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Adrenoceptor antagonists are a chemically _________ and _______ diverse group

A

heterogenous, structurally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

These drugs are predominantly…

A

Competitive antagonists

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Phenoxybenzamine is what type of pharmaceutical agent?

A

Beta-haloethylamine alkylating agent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Phenoxybenzamine is an __________ antagonist, meaning you can not get the receptor free again; they are occupied and won’t be free again.

A

irreversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Phentolamine and Tolazoline are analogs of?

A

Imidazoline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Prazosin is a?

A

Piperazinyl quinozoline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phenothiazine tranquilizers are potent ____________ (e.g., ____________) and demonstrate substantial __________ __-receptor blocking effects (side effects). The ________ in peripheral vascular resistance secondary to ___________ of these receptors is clinically significant.

A

antagonists, Acepromazine, nonselective, α, decrease, antagonism

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Describe the cardiovascular effects of α-Adrenergic Receptor Antagonists.

α1-adrenergic receptor antagonists produces ________ of both _______ and ________ vessels
Following pretreatment with an α1-adrenergic receptor antagonists, increases in ___________
vascular resistance to _____-_______ administration are eliminated.

A

dilation, arterial, venous, peripheral, NE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Describe the EPI reversal effect.

A

Following pretreatment with an α1-adrenergic receptor antagonists, administration of EPI may induce a reduction in peripheral vascular resitance and marked vasodilation mediated by activation of β2 –adrenergic receptors ↓ arterial blood pressure

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

α1-adrenergic receptor antagonists decrease ?

A

resistance to urine flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

a2B-adrenergic receptor antagonists have a role as ____________ in platelets

A

antiaggregant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

α2-adrenergic receptor antagonists may stimulate ________ release from pancreatic _____ cells

A

insulin release from pancreatic islet cells

22
Q

α-adrenergic receptor antagonists produce ________ of the third eyelid, _____, and nasal ________.

A

protrusion, miosis, stuffiness

23
Q

α2-adrenergic receptor antagonists can reverse the ___________ mediated by α2-adrenergic receptor _______.

A

sedation, agonists

24
Q

Nonselective α1-α2 -antagonists
Phenoxybenzamine (α1___ α2 )
* Phenoxybenzamine binds _________ to α-adrenergic receptor and produces an _________ block. Once bound, it inhibits the __________ of NE at presynaptic nerve terminals. Additionally, Phenoxybenzamine acts to various degrees as an antagonist at ____________, ____________, and ___________
receptors.

A

> , covalently, irreversible, reuptake, histamine, acetylcholine, and serotonine

pheochromocytoma = tumor in? –> high amount of nor epi in blood. to revert effect of high Norepi, we need to use antagonist

25
The predominant use of phenoxybenzamine in veterinary medicine is to ?
manage the symptoms of catecholamine excess in the treatment of patients with a pheochromocytoma. Phenothiazine tranquilizers and tetracyclic antidepressant trazodone
26
α-Adrenergic Receptor Antagonists Selective α1-antagonists Prazosin (____) has been used: 1. For the treatment of __________. Prazosin _______ arterial and venous _______ muscle 2. To decrease _________ to ______ flow in dogs with functional urethral ___________, prostatic _________, idiopathic ___________ reflex _________.
α1 1. hypertension, relaxes, smooth 2. resistance, urine, obstruction, hyperplasia, vesicourethral, dyssynergia
27
___________ ________ is thought to play a role in urethral obstruction recurrence. The ___-receptor blockade is a useful component of post-obstruction therapy.
Urethral spasm, α1
28
Prazosin is a ____________ ___-antagonist. It has a higher ___–adrenergic receptor affinity than _______________. The administration of prazosin to dogs results in a greater reduction of __________ pressure than _______________. The efficacy of this drug in the treatment of urethral obstruction in cats is debated due to their ?
selectiv a1, α1, phenoxybenzamine, urethral, phenoxybenzamine, anatomy (distal urethra)
29
List the Important limitation to using α1–adrenergic receptor antagonists for urethral relaxation. Lead to ______________ effects: * Reduces vascular _______ muscle _____ * Decreases in ________, ________, and ______ arterial blood pressure
Lead to cardiovascular effects: * Reduces vascular smooth muscle tone * Decreases in systolic, diastolic, and mean arterial blood pressure
30
Tamsulosin and silodosin are _____________ __-antagonists 1. Tamsulosin is a _________-generation ___-adrenergic receptor ________. 2. Tamsulosin has a higher affinity for _____ subtype (found in the urethra and prostate of humans and dogs) than for the ______ subtype (in vascular smooth muscle) 3. Silodosin is a _____-generation, highly selective ____-receptor ________. 4. Dogs with or without prostatic _________ demonstrated a similar response to silodosin or tamsulosin on decreasing ___________ pressure.
selective, a1, second, α1, antagonist, α1A, α1B, third, α1, antagonist, hyperplasia, intraurethral
31
Yohimbine, tolazoline, and atipamezole are _____________ ___-antagonists and are used to ______ the sedative effects of α2-adrenergic agonists such as ?
Selective, a2, reverse, xylazine, medetomidine, dexmedetomidine, detomidine, and romifidine
32
α-Adrenergic Receptor Antagonists Selective α2-antagonists 1. Yohimbine is an _________ alkaloid found in the bark of the tree ____________ ______ and in ___________ ______. It can cause CNS __________, _______ heart rate, and _________ blood pressure by increasing _____ release from adrenergic nerves. 2. Yohimbine can increase GI ______ by increasing ____________ tone 3. Yohimbine also demonstrates a degree of _________ activity at serotonin receptors 4. It is less used in ____ animals patients (atipamezole). The efficacy for reversal of xylazine in cattle is variable
1. indolealkylamine, Pausinystalia yohimbe, Rauwolfia root, stimulation, increased, increased, NE 2. motility, parasympathetic 3. antagonistic 4. small
33
Tolazoline is a ________, _______ ____ –and ____ adrenergic antagonist (___________ derivatives) * Tolazoline injection is approved for reversing ________ in horses * Tolazoline is also used off-label to reverse other ____-_________ agonists in equids such as detomidine. Its effect is _______ and _________. * Tolazoline can be an alternative to __________ in reversing sedation in large animals and wildlife animals (less _________).
mixed, synthetic, α2, α1, imidazoline, xylazine, α2, adrenergic, transient, incomplete, atipamezole, expensive
34
Atipamezole was originally approved to reverse the sedative and analgesic effect of _______________ _____________. Atipamezole is more potent than _________: reverses sedation induced by ___-_______, at ____-_____ the dose required for yohimbine. * It has been used off-label in dogs to treat __________ by __________ decongestants (e.g., ?) * It has been used off-label to treat intoxication from the ________/______, ____ (α2-receptor agonist) * It is effective in ____ species, including _____.
medetomidine, hydrochloride, yohimbine, α2, agonists, one-tenth, intoxication, imidazoline, oxymetazoline, tetrahydrozoline, xylometazoline, insecticide, acaricide, amitraz, all, ruminants
35
β-Adrenergic Receptor Antagonists β-adrenergic receptor antagonists are structurally similar to ____________ * Most of the available drugs are pure _________ * Some β-adrenergic antagonists exhibit ___________-___________ activity (similar to local anesthetics) * There are β-adrenoceptor blockers classified as _______ ________ (they favor the ______ conformation). * There are several that are partial β-adrenergic receptor agonists: a) They cause a _____ activation (not as a full agonist such as EPI) b) They ______ the activation of β-Adrenergic receptor in the presence of high levels of ? Intrinsic sympathetic activity (ISA)?
catecholamines, antagonists, membrane, stabilizing, inverse, agonists, inactive, partial, inhibit, EPI and NE
36
37
Antagonism of cardiac β-adrenergic receptors slows __________ conduction and produces negative _______, ________ effects both decrease?
atrioventricular, inotropic chronotropic, cardiac output
38
β-blocking drugs when administered chronically may ____ _________ __________ in hypertensive patients. ___________ peripheral vascular resistance is often an acute effect observed.
↓blood pressure, Increased
39
List the Pulmonary effects of administering B-blocking drugs. Nonselective β-adrenergic receptor antagonists will ______ β2-receptors in bronquial ________ muscle --> ___________ and ________ airway resistance ?
Nonselective β-adrenergic receptor antagonists will block β2-receptors in bronquial smooth muscle Bronchoconstriction and increased airway resistance
40
β-Adrenergic Receptor Antagonists Effects on the eye Topical administration of β-adrenergic receptors antagonists: * Reduce intraocular ______ by blocking ___ released from ________ nerve endings * ________ in aqueous humor production Metabolic and endocrine effects * β-adrenergic receptors antagonists inhibit the activation of ______ and ________ * Nonselective β-adrenergic antagonists may delay recovery from ___________ (type-1 ___ type-2 diabetes mellitus
pressure, NE, sympathetic, Decreases, lipolysis, glycogenolysis, hypoglycemia, >
41
β-Adrenergic Receptor Antagonists β-adrenergic receptor antagonists are classified as:
1. Nonselective β-adrenergic receptor antagonists → first generation 2. β1-selective receptor antagonists → second generation 3. Nonselective (or subtype selective) β-adrenergic receptor antagonists with additional cardiovascular actions unrelated to β-adrenergic receptor blockade → third generation Most frequently used drugs in veterinary patients include: Propranolol, atenolol, esmolol, metoprolol, and carvedilol
42
β-Adrenergic Receptor Antagonists 1. Nonselective β-adrenergic receptor antagonists → _____ generation Propranolol * Competitive ________ with no intrinsic ________ activity (ISA) * Blocks both __ and ___ receptors * Recent evidence indicates propranolol is an _____ agonist of β-receptors * It has membrane- _________ activity * Today, with the development of more selective β-adrenergic receptor antagonists its use is ____ frequent Pharmacological effects: * Propanolol decreases the _____ heart rate and depresses __-__ conduction * It decreases cardiac ______ * It decreases myocardial ______ demand * It increases airway ________
first, antagonist, sympathetic, β1, β2, inverse, stabilizing, less, sinus, A-V , output, oxygen, resistance
43
β-Adrenergic Receptor Antagonists Propranolol It has been administered IV, IM, SC, or orally in the treatment of: ?? * ______arrhythmias * _______tension * _____throphic and __________ cardiomyopathies * Cardiovascular consequences of _________ or ____________ Side effects: * Upregulation of β-adrenergic receptors occurs with long-______ therapy * _______ cessation of therapy leads to excessive stimulation of β-adrenergic receptors * Propanolol may cause ________ and is contraindicated in asthmatic animals
Tachy, Hyper, Hyper, obstructive, thyrotoxicosis, pheochromocytoma term, Abrupt, bronchospasm
44
β-Adrenergic Receptor Antagonists 2. β1-selective receptor antagonists → ________ generation Metoprolol * It does not exhibit intrinsic ________ activity (ISA) * At ____ doses it blocks β2 receptors * Metoprolol does not possess membrane- _________ activity Pharmacological effects: * Decreased ____ heart rate and slowed ___--___ conduction * ________ cardiac output * Decreased myocardial _____ demand * ______ blood pressure * ___________ of the β-agonist-induced tachycardia
second, sympathetic, high, stabilizing, sinus, A-V, Disminished, oxygen, Reduced, Inhibition
45
β-Adrenergic Receptor Antagonists Metoprolol can be used orally to treat: * ______________ tachyarrhythmias * _________ ventricular contractions * ___________ hypertension * ____________ cardiomyopathy * _____________ in cats Metoprolol is relatively safe to use in animals with __________ disease
Supraventricular, Premature, Systemic, Hyperthrophic, Thyrotoxicosis, bronchospastic
46
β-Adrenergic Receptor Antagonists Atenolol * Atenolol does not have intrinsic _______ activity (ISA) * It decreases heart _____, cardiac _____, and ______ and ______ pressures Atenolol is administered orally to treat: ? * _________ arrhythmias * Systemic _______ * _________ cardiomyopathy in cats Side effects: * It should be used cautiously in animals with _______ or a history of ______. At high doses it can block ___ receptors * Excessive ___-blockade can greatly reduce cardiac output * It must be used with caution in patients with ________ heart failure, in _____ failure patients * Atenolol can cause ?
sympathetic, rate, output, systolic, diastolic, Supraventricular, hypertension, Hyperthrophic asthma, bronchospams, β2, β1, congestive, renal, lethargy, hypotension, or diarrhea
47
β-Adrenergic Receptor Antagonists 2. β1-selective receptor antagonists → ______ generation Esmolol * It has little membrane-_________ activity * It is an ultra-______-acting β1-selective receptor antagonist (~____ min.) Therapeutic uses: * Esmolol and propranolol are the first choices for IV use for _______________ * Ventricular outflow obstruction in _____ Side effects: * Excessive β1-blockade can greatly reduce ?
second, stabilizing, short, 20, tachyarrhythmias, cats, cardiac output
48
β-Adrenergic Receptor Antagonists 3. Nonselective β-receptor antagonists → ______ generation Carvedilol * Demostrates modest ____-adrenergic receptor antagonist properties * Carvedilol demostrates membrane __________ activity but no intrinsic sympathetic activity * As carvedilol also inhibits α1-adrenergic activity, it can cause ___________ and reduce _________. * Carvedilol has free radical ___________ and ____________ effects * β-adrenergic blockade, reduces effects of ________ stimulation Therapeutic uses: * Used as an anti- ________ drug * In the longterm management of ?
third, α1, stabilizing, vasodilation, afterload, scavenging, antidysrhythmic, sympathetic, arrhythmic, dilated cardiomyopathy and chronic valve disease
49
Clinical Uses of β-Adrenergic Receptor Antagonists Acquired cardiac disease in dogs * Studies in heart failure patients have demostrated that β-adrenoceptor antagonism with selective (_____)- receptor antagonists or ____-generation antagonists reduce mortality and increase quality of life * The treatment of heart failure was earlier avoided due to the ______ inotropic effects, _________, and _______. The availability of more β1-receptor selective drugs have __________ these complications * _________ _________ _______ disease (CMVD) is the most common cause of heart disease and CHF in dogs, followed by ________ cardiomyopathy (DCM) * Dogs with mitral valve disease that were treated with orally adm. of _________ had improvement in quality life scores and a modest reduction in systolic blood pressure
β1, third, negative, hypotension, bronchspasm, reduced, Chronic mitral valvular, dilated, carvedilol
50
Clinical Uses of β-Adrenergic Receptor Antagonists Hypertrophic cardiomyopathy (HCM) and ventricular outflow obstruction * HCM is the most common cardiac disease in ____. A high percentage of affected cats will also develop ? * HCM and hypertrophic obstruction cardiomyopathy (HOCM) are characterized by ? * The most commonly prescribed medications used to reduce dynamic LVOT obstruction in cats with HCM are ? * Subaortic stenosis (SAS) in dogs is a ______ cardiac abnormality that causes varying degree of _____ obstruction. Dogs with severe SAS have been treated with __-blockers, most commonly _______
cats, dynamic obstruction of the left ventricular outflow tract (LVOT), concentric ventricular hypertrophy β-adrenergic receptor antagonists, particularly atenolol congenital, LVOT, β, atenolol
51